{"id":5886,"date":"2024-12-02T15:23:45","date_gmt":"2024-12-02T21:23:45","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5886"},"modified":"2025-06-27T08:31:42","modified_gmt":"2025-06-27T13:31:42","slug":"nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u30d7\u30ed\u30b0\u30e9\u30e0\u304cFLORetina 2024\u4f1a\u8b70\u3067\u7d39\u4ecb\u3055\u308c\u308b"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p>\u30c0\u30e9\u30b9\u30012024\u5e7412\u67082\u65e5 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/ja\/\">\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>\u907a\u4f1d\u6027\u7db2\u819c\u75be\u60a3\uff08IRD\uff09\u304a\u3088\u3073\u9ec4\u6591\u5909\u6027\u306b\u4f34\u3046\u5730\u56f3\u72b6\u840e\u7e2e\uff08GA\uff09\u306e\u907a\u4f1d\u5b50\u6cbb\u7642\u3092\u958b\u767a\u3057\u3066\u3044\u308b\u81e8\u5e8a\u6bb5\u968e\u306e\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b\u306f\u3001\u672c\u65e5\u3001\u30b8\u30e7\u30eb\u30c7\u30a3\u30fb\u30e2\u30cd\u30b9\u304c\u5e74\u6b21\u7dcf\u4f1a\u3067\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u81e8\u5e8a\u30c7\u30fc\u30bf\u306e\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u3092\u884c\u3046\u3053\u3068\u3092\u767a\u8868\u3057\u307e\u3057\u305f\u3002\u00a0<a href=\"https:\/\/floretina.com\/\">FLORetina\u30ab\u30f3\u30d5\u30a1\u30ec\u30f3\u30b9\u00a0<\/a>12\u67085\u65e5\u306b\u958b\u50ac<sup>\u756a\u76ee<\/sup>-8<sup>\u756a\u76ee<\/sup>\u00a0\u30a4\u30bf\u30ea\u30a2\u306e\u30d5\u30a3\u30ec\u30f3\u30c4\u30a7\u306b\u3042\u308b\u30d0\u30c3\u30bd\u8981\u585e\u3067\u958b\u50ac\u3055\u308c\u307e\u3059\u3002\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\u306f\u6b21\u306e\u3068\u304a\u308a\u3067\u3059\u3002<\/p>\n<p><strong>\u30bf\u30a4\u30c8\u30eb\uff1a<\/strong>\u00a0<a href=\"https:\/\/www.floretina.com\/floretinaicoormeeting2024\/slotprogram?slotid=2886\">\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u306b\u5bfe\u3059\u308b\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e MCO-010 \u5149\u907a\u4f1d\u5b66\u7684\u7642\u6cd5\u306e\u9577\u671f\u7684\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027: \u9577\u671f\u8ffd\u8de1\u8abf\u67fb (REMAIN) \u304b\u3089\u306e 126 \u9031\u9593\u306e\u7d50\u679c<\/a><\/p>\n<p><strong>\u30bb\u30c3\u30b7\u30e7\u30f3\u30bf\u30a4\u30c8\u30eb<\/strong>: Retina Futura\u3001\u30bb\u30c3\u30b7\u30e7\u30f3 1<br \/>\n<strong>\u30bb\u30c3\u30b7\u30e7\u30f3\u65e5:\u00a0<\/strong>12\u67086\u65e5<sup>\u756a\u76ee<\/sup>, 2024<br \/>\n<strong>\u30bb\u30c3\u30b7\u30e7\u30f3\u6642\u9593:\u00a0<\/strong>\u5348\u5f8c12\u664218\u5206\uff08\u4e2d\u592e\u30e8\u30fc\u30ed\u30c3\u30d1\u590f\u6642\u9593\uff09<br \/>\n<strong>\u4f4d\u7f6e\uff1a<\/strong> \u30b5\u30f3\u30fb\u30b8\u30e7\u30f4\u30a1\u30f3\u30cb\u30fb\u30eb\u30fc\u30e0\u3001\u30d0\u30c3\u30bd\u8981\u585e\u3001\u30d5\u30a3\u30ec\u30f3\u30c4\u30a7<br \/>\n<strong>\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/strong>\u30b8\u30e7\u30eb\u30c7\u30a3\u30fb\u30e2\u30cd\u30b9\u533b\u5b66\u535a\u58eb\u3001\u30de\u30ad\u30e5\u30e9\u7814\u7a76\u6240\u6240\u9577\u3001\u30d0\u30eb\u30bb\u30ed\u30ca\u30fb\u30de\u30ad\u30e5\u30e9\u8ca1\u56e3\uff08\u30b9\u30da\u30a4\u30f3\uff09<\/p>\n<p>RESTORE\u591a\u65bd\u8a2d\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u6a21\u64ec\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u3067\u3001Multi-Characteristic Opsin (MCO-010) \u3067\u6cbb\u7642\u3057\u305f\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7 (RP) \u60a3\u8005\u306b\u304a\u3051\u308b\u6700\u9ad8\u77ef\u6b63\u8996\u529b (BCVA) \u306e\u7d71\u8a08\u7684\u306b\u6709\u610f\u306a\u6539\u5584\u304c\u89b3\u5bdf\u3055\u308c\u305f\u3053\u3068\u306b\u52a0\u3048\u3001\u30e2\u30cd\u30b9\u535a\u58eb\u306f\u3001REMAIN\u9577\u671f\u8ffd\u8de1\u8abf\u67fb\u3067\u89b3\u5bdf\u3055\u308c\u305f126\u9031\u9593\u307e\u3067\u306e\u6301\u7d9a\u7684\u306a\u6709\u52b9\u6027\u3068\u5b89\u5168\u6027\u3092\u767a\u8868\u3057\u307e\u3059\u3002<\/p>\n<p><strong>Nanoscope Therapeutics, Inc. \u306b\u3064\u3044\u3066<br \/>\n<\/strong>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u6cbb\u7642\u6cd5\u306e\u306a\u3044\u7db2\u819c\u5909\u6027\u75be\u60a3\u3067\u5931\u660e\u3057\u305f\u4f55\u767e\u4e07\u4eba\u3082\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u30aa\u30d7\u30c8\u30b8\u30a7\u30cd\u30c6\u30a3\u30c3\u30af\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u5bfe\u3059\u308bRESTORE\u30d5\u30a7\u30fc\u30ba2b\u591a\u65bd\u8a2d\u30e9\u30f3\u30c0\u30e0\u5316\u4e8c\u91cd\u76f2\u691c\u507d\u5bfe\u7167\u81e8\u5e8a\u8a66\u9a13\u306e\u826f\u597d\u306a\u8a66\u9a13\u7d42\u4e86\u7d50\u679c\u3092\u53d7\u3051\u3066\uff08<a href=\"https:\/\/c212.net\/c\/link\/?t=0&l=en&o=4297362-1&h=1116881864&u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3939588-1%26h%3D1414634841%26u%3Dhttps%253A%252F%252Fc212.net%252Fc%252Flink%252F%253Ft%253D0%2526l%253Den%2526o%253D3823946-1%2526h%253D153867349%2526u%253Dhttps%25253A%25252F%25252Fclinicaltrials.gov%25252Fct2%25252Fshow%25252FNCT04945772%25253Fterm%25253DNanoscope%252526draw%25253D2%2526a%253DNCT04945772%26a%3DNCT04945772&a=NCT04945772\">NCT04945772<\/a>\uff09\u3001\u540c\u793e\u306f\u3001\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-announces-plans-to-submit-bla-for-mco-010-to-treat-retinitis-pigmentosa-302270593.html\">RP\u6cbb\u7642\u85acMCO-010\u306eBLA\u7533\u8acb<\/a>\u00a0\u540c\u793e\u306f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305fMCO-010\u7642\u6cd5\u306e\u7b2c2\u76f8STARLIGHT\u8a66\u9a13\u3092\u5b8c\u4e86\u3057\u305f\uff08<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\">NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0<a href=\"https:\/\/www.prnewswire.com\/news-releases\/nanoscope-therapeutics-announces-end-of-phase-2-meeting-with-us-fda-and-plan-to-initiate-a-phase-3-clinical-trial-of-mco-010-to-treat-stargardt-macular-degeneration-302247017.html\">\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02025\u5e74\u7b2c1\u56db\u534a\u671f\u306b\u767a\u58f2\u4e88\u5b9a\u3067\u3059\u3002MCO-010\u306f\u3001RP\u3068Stargardt\u306e\u4e21\u65b9\u3067FDA\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u6307\u5b9a\u3068FDA\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u524d\u81e8\u5e8a\u8cc7\u7523\u306b\u306f\u3001GA\u5411\u3051\u306e\u975e\u30a6\u30a4\u30eb\u30b9\u6027\u30ec\u30fc\u30b6\u30fc\u9001\u9054MCO-020\u907a\u4f1d\u5b50\u6cbb\u7642\u304c\u542b\u307e\u308c\u307e\u3059\u3002<\/p>\n<p><strong>\u6295\u8cc7\u5bb6\u9023\u7d61\u5148:<\/strong><br \/>\n\u30a2\u30eb\u30b4\u30c3\u30c8\u30d1\u30fc\u30c8\u30ca\u30fc\u30ba<br \/>\n212-600-1902<br \/>\n<a href=\"mailto:PR@nanostherapeutics.com\">PR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS, Dec. 2, 2024 \u00a0\u2014 Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA) secondary to macular degeneration, today announced that Jordi Mon\u00e9s will provide a presentation of Nanoscope clinical data at the annual\u00a0FLORetina conference\u00a0taking place on\u00a0December 5th-8th\u00a0at the Fortezza da Basso in\u00a0Florence Italy. Details for the presentation are as follows: Title:\u00a0Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients With Severe Vision Loss Due to Retinitis Pigmentosa: 126-Week Results From a Long-Term Follow-Up Study (REMAIN) Session Title: Retina Futura, Session 1 Session Date:\u00a0December 6th, 2024 Session Time:\u00a012:18 pm CEST Location: San Giovanni room,\u00a0Fortezza da Basso, [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5889,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5886","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T21:23:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T13:31:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress\",\"datePublished\":\"2024-12-02T21:23:45+00:00\",\"dateModified\":\"2025-06-27T13:31:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"},\"wordCount\":319,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\",\"name\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"datePublished\":\"2024-12-02T21:23:45+00:00\",\"dateModified\":\"2025-06-27T13:31:42+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/NSCOPE_LI_Mondes_FLORetina.jpg\",\"width\":1200,\"height\":800},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/12\\\/02\\\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u30d7\u30ed\u30b0\u30e9\u30e0\u304cFLORetina 2024\u5b66\u4f1a\u3067\u7d39\u4ecb\u3055\u308c\u308b\u4e88\u5b9a - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-12-02T21:23:45+00:00","article_modified_time":"2025-06-27T13:31:42+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress","datePublished":"2024-12-02T21:23:45+00:00","dateModified":"2025-06-27T13:31:42+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"},"wordCount":319,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","url":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306e\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\u30d7\u30ed\u30b0\u30e9\u30e0\u304cFLORetina 2024\u5b66\u4f1a\u3067\u7d39\u4ecb\u3055\u308c\u308b\u4e88\u5b9a - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","datePublished":"2024-12-02T21:23:45+00:00","dateModified":"2025-06-27T13:31:42+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/12\/NSCOPE_LI_Mondes_FLORetina.jpg","width":1200,"height":800},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/12\/02\/nanoscopes-retinitis-pigmentosa-program-to-be-featured-at-floretina-2024-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope\u2019s Retinitis Pigmentosa Program to be Featured at FLORetina 2024 Congress"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=5886"}],"version-history":[{"count":4,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5886\/revisions"}],"predecessor-version":[{"id":9009,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/5886\/revisions\/9009"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/5889"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=5886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=5886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=5886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}